Protagonist Therapeutics (PTGX) Tops Q3 EPS by 4c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q3 EPS of ($0.54), $0.04 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $4.68 million versus the consensus estimate of $1 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• TechCreate Group faces NYSE American delisting proceedings
• Frequency Electronics secures $10 million credit facility with JPMorgan